Published in

Impact Journals, Oncotarget, 41(8), p. 69779-69796, 2017

DOI: 10.18632/oncotarget.19266

Links

Tools

Export citation

Search in Google Scholar

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Journal article published in 2017 by Maryam Zanjirband, Nicola Curtin, Richard J. Edmondson ORCID, John Lunec
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO